Skip Navigation Links
Skip Navigation Links

Head & Neck Cancer

MATCH: Molecular analysis for therapy choice. Targeted therapy directed by genetic testing in treating patients with advanced refractory solid tumors or lymphoma.  EAY131 (NCT02465050)  (MBMC Contact: Chris Sanders 314-996-5802) 

Randomized Phase III trial of mematine and whole-brain radiotherapy with or without hippocampal avoidance in patients with brain metastases  NRG-CC001 (NCT02360215 )  (MBMC Contact:  Diana Christian 314-996-5888)  (Requires radiation oncologist to undergo training and specialized MRIs - approved at MBMC)

Phase III Randomized Study of Adjuvant Intensity-Modulated Radiotherapy With Versus Without Cetuximab in Patients With Locally Advanced Resected Squamous Cell Carcinoma of the Head and Neck  (Cetuximab Provided)   RTOG 0920 (NCT00956007)  (MBMC Contact: Chris Sanders 314-996-5802)   (RTOG Credentialing Required for Affiliate Sites Prior to Patient Registration - See Protocol)

Phase II randomized trial of adjuvant radiotherapy with or without cisplatin for p53 mutated, surgically resected squamous cell carcinoma of the head and neck  EA3132 (NCT02734537)  MBMC Contact Chris Sanders 314-996-5802)   (RT credentialed at MBMC and Southeast, Cap Region pending).

Head and Neck Cancer Trials in St. Louis, MO

All contents 2007 Heartland Cancer Research St. Louis, MO. All rights reserved. Privacy Policy